<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093728</url>
  </required_header>
  <id_info>
    <org_study_id>D1532C00083</org_study_id>
    <nct_id>NCT02093728</nct_id>
  </id_info>
  <brief_title>To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers</brief_title>
  <official_title>A Phase I, Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inhibitor Itraconazole and the CYP2C19 Inhibitor Fluconazole on the Pharmacokinetics of a 25 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the effect of Itraconazole and Fluconazole on the pharmacokinetics of
      Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Male Volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inhibitor Itraconazole
      and the CYP2C19 Inhibitor Fluconazole on the Pharmacokinetics of a 25 mg Single Oral Dose of
      Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assessment of area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of area under the plasma concentration-time from time zero to the time of the last quantifiable concentration (AUC(0-t)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of area under the plasma concentration-time curve from time zero to 12 hours post-dose AUC(0-12)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of maximum plasma concentration (Cmax)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of time to Cmax (tmax)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib by assesement of apparent oral plasma clearance (CL/F)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib by assesement of apparent volume at distribution steady state, (MRT)*CL/F (Vss/F)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib by assesement of apparent volume at distribution (Vz/F)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of terminal half-life (t1/2)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of terminal rate constant (Î»z)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of AUC metabolite to parent ratio (MRAUC)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assesement of Cmax metabolite to parent ratio (MRCmax)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of selumetinib by assesement of mean residence time (MRT)</measure>
    <time_frame>Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 72 and 96 hours post dose</time_frame>
    <description>Samples taken during each of the 6 treatments</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety variables (adverse events, physical examinations, opthalmologic assessements, vital signs, clinical laboratory assessments and 12 lead electrocardiograms)</measure>
    <time_frame>Baseline (Day-1) up to Day 24</time_frame>
    <description>Assessments performed during each of the 6 treatments</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Solid Tumours</condition>
  <arm_group>
    <arm_group_label>selumetinib; itraconazole; selumetinib + itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive selumetinib 25mg alone; itraconazole 200mg pre-dosing; selumetinib 25mg and itraconazole 200mg; all adminstered by mouth as a capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>selumetinib; fluconazole; selumetinib + fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive selumetinib 25mg alone administered by mouth as a capsule; fluconazole 400mg and fluconazole 200mg pre-dosing, administered by mouth as a tablet; selumetinib 25mg and fluconazole 200mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selumetinib</intervention_name>
    <description>Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A</description>
    <arm_group_label>selumetinib; itraconazole; selumetinib + itraconazole</arm_group_label>
    <other_name>(AZD6244; ARRY-142866) ( Hyd-Sulfate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:</description>
    <arm_group_label>selumetinib; itraconazole; selumetinib + itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.</description>
    <arm_group_label>selumetinib; itraconazole; selumetinib + itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selumetinib</intervention_name>
    <description>Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.</description>
    <arm_group_label>selumetinib; itraconazole; selumetinib + itraconazole</arm_group_label>
    <other_name>(AZD6244; ARRY-142866) ( Hyd-Sulfate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selumetinib</intervention_name>
    <description>Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.</description>
    <arm_group_label>selumetinib; fluconazole; selumetinib + fluconazole</arm_group_label>
    <other_name>(AZD6244; ARRY-142866) ( Hyd-Sulfate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
    <description>Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.</description>
    <arm_group_label>selumetinib; fluconazole; selumetinib + fluconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
    <description>Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E</description>
    <arm_group_label>selumetinib; fluconazole; selumetinib + fluconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selumetinib</intervention_name>
    <description>Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E</description>
    <arm_group_label>selumetinib; fluconazole; selumetinib + fluconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: 1. Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive) and
        weigh at least 50 kg and no more than 100 kg. 2. Female subjects of non-childbearing
        potential. 3. Have a calculated creatinine clearance (CrCL) &gt;50 mL/min using the
        Cockcroft-Gault formula.

        Exclusion Criteria: 1. Subjects of Japanese or non-Japanese Asian ethnicity. 2. Any one
        parent or grandparent (maternal or paternal) is Japanese or non-Japanese. Asian (ie, China,
        Taiwan, Korea, Philippines, Thailand, Vietnam and Malaysia). Asian Indians are acceptable.
        3. Current or past history of central serous retinopathy or retinal vein
        thrombosis,intra-ocular pressure &gt;21 mmHg or uncontrolled glaucoma. 4. Any clinically
        relevant abnormal findings in physical examination, hematology, clinical chemistry,
        urinalysis, vital signs or ECG at baseline in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles 6700 W 115th Street, Kansas, US</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2514&amp;filename=CSR_Synopsis_D1532C00083.pdf</url>
    <description>CSR_Synopsis_D1532C00083</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I, healthy, pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

